Aurobindo consolidated Q2 profit before tax up 5.9% at Rs 904 crore

Gross profit margin slipped to 20.8% during the quarter under review from 21.6% in the year-ago previous quarter owing to higher expenditure, which grew by 19%

Indian drug major Aurobindo Pharma Limited has reported a 5.9 per cent increase in consolidated profit before tax (before forex and exceptional items) at Rs 903.8 crore for the quarter ended September, 2019 as compared with Rs 853.2 crore in the corresponding quarter previous year.

Revenues from operations grew 17.9 per cent to Rs 5,600 crore as compared to Rs 4,751 crore in the year ago period on the back of a strong revenue growth from US and European markets.

Even though the company performed well on the revenue front, the gross profit margin marginally slipped to 20.8 per cent